Vigonvita Life Sciences Co Ltd, an SIP-headquartered biomedicine company, went public on the Main Board of the HKEX on Nov 6, becoming the fifth company from SIP to go public this year. So far, SIP is home to 71 companies listed at home and abroad.

Founded in 2013, Vigonvita is committed to improving patients’ health and quality of life by developing innovative small-molecule drugs for treatment of neuropsychiatric diseases and viral infections as well as reproductive health.

The company has established a comprehensive, in-house system covering the entire drug development chain from new drug discovery and druggability evaluation to preclinical and clinical studies, manufacturing and commercialization. Its competitive pipeline includes two products in the commercialization phase, four in clinical studies,and three in preclinical research.

Dr. Tian Guanghui, chairman and general manager of the company, said the successful listing on the HKEX will bankroll Vigonvita’s future R&D and accelerate the commercialization of its products.

November 6, 2025